Vanguard Asset Management
BEAM icon

Vanguard Asset Management’s Beam Therapeutics BEAM Stock Holding History

Vanguard Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
90,358
+9,661
+12% +$292K ﹤0.01% 1336
2026
Q1 		$1.92M Buy
+80,697
New +$2.24M ﹤0.01% 1490

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Asset Management's BEAM Position: Q2 2026 in Review

Vanguard Asset Management increased its Beam Therapeutics (BEAM) stake by 12% in Q2 2026, buying an estimated $292K and bringing the position to 90,358 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

Vanguard Asset Management first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Vanguard Asset Management held 90,358 shares of Beam Therapeutics worth $3.1M as of Q2 2026.
  • Vanguard Asset Management bought 9,661 Beam Therapeutics shares in Q2 2026, an estimated $292K.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1336 holding.
  • Vanguard Asset Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 273 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.